ClinicalTrials.gg
CompletedNCT06615557PALISADE-4Updated Nov 4, 2026

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

A Phase 3 interventional study of Fasedienol Nasal Spray and Placebo Nasal Spray in Social Anxiety Disorder (SAD), sponsored by VistaGen Therapeutics, Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by VistaGen Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026Now CompletedStudy completion movedGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-4 and choose to enter the distinct open-label extension phase of the study.

02

Conditions studied

  • Social Anxiety Disorder (SAD)

Keywords

  • Fasedienol
  • PH94B
  • social anxiety disorder
  • social anxiety
  • SAD
  • pherine
  • pherine nasal spray
  • acute treatment
  • anxiolytic
  • mental health
  • anxiety
  • performance anxiety
  • anxiety nasal spray
  • anxiety treatment
  • public speaking anxiety
  • social phobia
  • phobic disorders
  • mental disorder
  • speech task
03

In context

Phobia, Social

367 studies on the registry are indexed under Phobia, Social; 58 are open to participants now.

This study's enrollment of 238 is above the median of 76 across 338 interventional studies indexed under Phobia, Social.

Browse Phobia, Social studies →

Lead sponsor

VistaGen Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written provided prior to conducting any study-specific assessment.
  • Male and female adults, 18 through 65 years of age, inclusive.
  • Current diagnosis of SAD as defined in the , 5th Edition, and confirmed by the Mini-International Neuropsychiatric Interview (MINI).
  • Clinician-rated Liebowitz Social Anxiety Score (LSAS) total score ≥70 at Screening (Visit 1).
  • Clinician-rated Hamilton Depression Rating Scale (HAM-D) (17-items) total score \<16.
  • Female subjects of must be able to commit to the consistent and correct use of an effective method of throughout the study
  • Subjects must have normal olfactory function

Exclusion criteria

Exclusion Criteria:

  • Any history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, psychosis, anorexia or bulimia, premenstrual dysphoric disorder, autism spectrum disorder, or obsessive-compulsive disorder.
  • Any other current principal or personality disorder (previously known as Axis I or Axis II disorders), except for specific phobias or generalized anxiety disorder, provided that these are not the primary diagnosis.
  • Subjects who meet criteria for moderate or severe alcohol use disorder within the 1 year prior to study entry, or any use of illicit substances or tetrahydrocannabinol ("THC") within 2 months prior to study entry.
  • In the opinion of the investigator, the subject has a significant risk for suicidal behavior during the course of their participation in the study, or the subject is considered to be an imminent danger to themself or others.
  • nasal pathology or history of significant nasal trauma, nasal surgery, total anosmia, or nasal septum perforation that may have damaged the nasal chemosensory epithelium.
  • Two or more documented failed adequate treatment trials with a registered medication approved for SAD.
  • Currently receiving cognitive-behavioral therapy (CBT), exposure therapy, or acceptance and commitment therapy.
  • Subjects taking psychotropic medications within 30 days before Visit 2.
  • Use of any over-the-counter product, prescription product, off-label treatment, cannabidiol ("CBD"), or herbal preparation for treatment of the symptoms of anxiety or social anxiety within 30 days before Visit 2.
  • Prior participation in a clinical trial involving fasedienol.
  • Participation in any other clinical trial within the last 30 days or during the course of the current trial.
  • Subjects with a positive urine drug screen.
  • Women who have a positive urine pregnancy test.
  • Women who are currently breastfeeding are not eligible unless they are willing to stop breastfeeding for the duration of the study.
  • Subjects who have tested positive and/or have exhibited symptoms consistent with SARS-CoV-2 infection during the 4 weeks prior to Screening (Visit 1).
  • Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    Fasedienol Nasal Spray

    Drug: Fasedienol Nasal Spray

  • Experimental
    Placebo Nasal Spray

    Drug: Placebo Nasal Spray

Interventions

  • Nasal spray delivered 20 minutes before the PSC

  • DrugPlacebo Nasal Spray

    Nasal spray delivered 20 minutes before the PSC

06

What researchers measure

Primary outcomes

  1. Subjective Units of Distress Scale (SUDS)

    The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt).

    Time frame: 7 days (Visit 2 to Visit 3)

Secondary outcomes

  1. Global Impression Scale of Improvement (CGI-I)

    The CGI-I scale is a clinician-rated scale to assess illness improvement. The CGI-I scale includes one item being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change.

    Time frame: 7 days (Visit 2 to Visit 3)

  2. Patient Global Impression of Change (PGI-C)

    The PGI-C is a patient self-rated scale to assess improvement. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change.

    Time frame: 7 days (Visit 2 to Visit 3)

07

Study locations

26 sites
  • Vistagen Clinical Site
    Phoenix, Arizona 85012, United States
  • Vistagen Clinical Site
    Little Rock, Arkansas 72211, United States
  • Vistagen Clinical Site
    Bellflower, California 90706, United States
  • Vistagen Clinical Site
    Oceanside, California 92056, United States
  • Vistagen Clinical Site
    Orange, California 92868, United States
  • Vistagen Clinical Site
    Redlands, California 92374, United States
  • Vistagen Clinical Site
    Torrance, California 90504, United States
  • Vistagen Clinical Site
    Denver, Colorado 80209, United States
  • Vistagen Clinical Site
    Tampa, Florida 33629, United States
  • Vistagen Clinical Site
    Decatur, Georgia 30030, United States
  • Vistagen Clinical Site
    Chicago, Illinois 60640, United States
  • Vistagen Clinical Site
    Naperville, Illinois 60563, United States
  • Vistagen Clinical Site
    Boston, Massachusetts 02131, United States
  • Vistagen Clinical Site
    Bloomfield Township, Michigan 48302, United States
  • Vistagen Clinical Site
    Flowood, Mississippi 39232, United States
  • Vistagen Clinical Site
    Las Vegas, Nevada 89119, United States
  • Vistagen Clinical Site
    Las Vegas, Nevada 89121, United States
  • Vistagen Clinical Site
    Albuquerque, New Mexico 87109, United States
  • Vistagen Clinical Site
    New York, New York 10128, United States
  • Vistagen Clinical Site
    Cincinnati, Ohio 45229, United States
  • Vistagen Clinical Site
    Austin, Texas 78737, United States
  • Vistagen Clinical Site
    Austin, Texas 78759, United States
  • Vistagen Clinical Site
    Dallas, Texas 75251, United States
  • Vistagen Clinical Site
    Houston, Texas 77055, United States
  • Vistagen Clinical Site
    San Antonio, Texas 78229, United States
  • Vistagen Clinical Site
    Everett, Washington 98201, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Study completion
Apr 2027→Jul 14, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Active, not recruiting→Completed
    Study completion Apr 2027→Jul 14, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06615557
Lead sponsor
VistaGen Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Sep 16, 2024
Primary completion
Apr 21, 2026
Completion
Jul 14, 2026
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fasedienol

Start the discussion